SlideShare a Scribd company logo
1 of 49
AN  INNOVATIVE APPROACH TOWARDS THE  TREATMENT of HEPATITIS C Prof. Dr. Aftab Mohsin  Medical Unit III Services Hospital, Lahore.
Pakistan: A Cirrhotic State
BACKGROUND Hepatitis C related chronic liver disease is common and may result in  devastating outcome.  The standard treatment World wide is Interferon and Ribavirin combination.
A PARADIGM SHIFT ! ,[object Object],[object Object]
HYDROLYTIC ENZYMES + RUTOSID … .a new perspective in the management of  Hepatitis C viral infections
HYDROLYTIC ENZYMES +RUTOSID  BIOLOGICAL RESPONSE MODIFIER  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
HYDROLYTIC ENZYMES +RUTOSID  BIOLOGICAL RESPONSE MODIFIER  ,[object Object],[object Object]
HYDROLYTIC ENZYMES +RUTOSID  BIOLOGICAL RESPONSE MODIFIER  ,[object Object],[object Object],[object Object]
Phlogenzym  ®   with INTERFERON+RIBAVIRIN;   a comparative study of efficacy and tolerability in patients with HCV infection
OBJECTIVE To compare the efficacy & tolerability of   Phlogenzym  ®     vs  standard therapy  (Interferon & Ribavirin)   in patients with HCV infections.   Phlogenzym ®  vs  INTERFERON+RIBAVIRIN
STUDY OVERVIEW Idea   Conceived In July 2003 Principal Investigator Identified 05-01-04 IRB –Approval 18-05-04 MoH Approval 25-03-05
  STUDY OVERVIEW Study Began 25-01-05 Patients Screened 12-02-05 First Patient  enrolled(V0) 27-03-05 First Patient completed(V6) 28-09-05 Study Presentation on 25-03-06
Phlogenzym ®  vs  INTERFERON+RIBAVIRIN ,[object Object],[object Object],[object Object],[object Object],[object Object]
Phlogenzym ®   vs  INTERFERON+RIBAVIRIN ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],Phlogenzym ®   vs  INTERFERON+RIBAVIRIN
Study Design   Phlogenzym ®   vs  INTERFERON+RIBAVIRIN For 6-months For 9-months Conventional Dosage 2 Tablets,3-times a day ½ hr before meals 30-patients recruited; 22-patients completed  39-patients recruited; 30  -patients completed. Interferon+Ribavirin Phlogenzym ®
b ,[object Object],[object Object],[object Object],Phlogenzym ®   vs  INTERFERON+RIBAVIRIN
[object Object],[object Object],[object Object],[object Object],Phlogenzym ®   vs  INTERFERON+RIBAVIRIN
Genotype Distribution in recruited patients Phlogenzym ®   vs  INTERFERON+RIBAVIRIN 1 0 1  2 2 3 17 25 3   6 4 Interferon Arm (Reference Drug) 6 6 Phlogenzym  Arm (Test Drug) Untypable 3  Description
Phlogenzym ®   vs  INTERFERON+RIBAVIRIN Genotype Distribution in recruited patients
Previous Medical History in Recruited Patients Phlogenzym ®   vs  INTERFERON+RIBAVIRIN 30 0 Interferon Arm (Reference Drug) 32 7 Phlogenzym  Arm (Test Drug) Naive Non Responders to Interferon Description
Previous Medical History in Recruited Patients Phlogenzym ®   vs  INTERFERON+RIBAVIRIN
COMPLIANCE STATUS   Phlogenzym ®   vs  INTERFERON+RIBAVIRIN 8 22 Interferon Arm (Reference Drug) 9 30 Phlogenzym  Arm (Test Drug) Dropped Out Trial Completed Description
DETAILS OF INTERFERON ARM  DROP OUT PATIENTS Phlogenzym ®   vs  INTERFERON+RIBAVIRIN Withdraw due to decrease TLC after 1 month of therapy 1 High grade fever after 1 month of therapy 1 Epistaxis after 1 month of therapy 1 H. Zoster after 4 months of therapy 1 Changed Physician after 1 month of therapy 4 REASONS ‘ n’
DETAILS OF  Phlogenzym ®   ARM  DROP OUT PATIENTS Phlogenzym ®   vs  INTERFERON+RIBAVIRIN Mild diarrhea, irritation or itching 3 No follow-up after 2 months of therapy 1 No follow-up after 3 months of therapy 1 No follow-up after 1 month of therapy 4 Reasons ‘ n’
GENDER DISTRIBUTION IN  PATIENTS WHO COMPLETED THERAPY Phlogenzym ®   vs  INTERFERON+RIBAVIRIN Mild diarrhea, irritation or itching 3 No follow-up after 2 months of therapy 1 No follow-up after 3 months of therapy 1 No follow-up after 1 month of therapy 4 Reasons ‘ n’ 14 8 Interferon Arm (Reference Drug) 13 17 Phlogenzym ®   Arm (Test Drug) Female Male Description
Phlogenzym ®   vs  INTERFERON+RIBAVIRIN GENOTYPE DISTRIBUTION IN  PATIENTS WHO COMPLETED THERAPY Mild diarrhea, irritation or itching 3 No follow-up after 2 months of therapy 1 No follow-up after 3 months of therapy 1 No follow-up after 1 month of therapy 4 Reasons ‘ n’ 2 2 3 12 20 3   5 3 Interferon Arm (Reference Drug) 4 4 Phlogenzym ®   Arm (Test Drug) Untypable 3  Description
Phlogenzym ®   vs  INTERFERON+RIBAVIRIN GENOTYPE DISTRIBUTION IN   PATIENTS WHO COMPLETED THERAPY Mild diarrhea, irritation or itching 3 No follow-up after 2 months of therapy 1 No follow-up after 3 months of therapy 1 No follow-up after 1 month of therapy 4 Reasons ‘ n’
PREVIOUS MEDICAL HISTORY IN   PATIENTS WHO COMPLETED THERAPY Phlogenzym ®   vs  INTERFERON+RIBAVIRIN Mild diarrhea, irritation or itching 3 No follow-up after 2 months of therapy 1 No follow-up after 3 months of therapy 1 No follow-up after 1 month of therapy 4 Reasons ‘ n’ 22 0 Interferon Arm (Reference Drug) 26 4 Phlogenzym ®   Arm (Test Drug) Naive Non Responders to Interferon Description
Phlogenzym ®   vs  INTERFERON+RIBAVIRIN PREVIOUS MEDICAL HISTORY IN  PATIENTS WHO COMPLETED THERAPY Mild diarrhea, irritation or itching 3 No follow-up after 2 months of therapy 1 No follow-up after 3 months of therapy 1 No follow-up after 1 month of therapy 4 Reasons ‘ n’
END OF TREATMENT RESPONSE ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Phlogenzym ®   vs  INTERFERON+RIBAVIRIN
PCR –VE PATIENTS DISTRIBUTION Phlogenzym ®   vs  INTERFERON+RIBAVIRIN Mild diarrhea, irritation or itching 3 No follow-up after 2 months of therapy 1 No follow-up after 3 months of therapy 1 No follow-up after 1 month of therapy 4 Reasons ‘ n’
[object Object],[object Object],[object Object],Phlogenzym ®   vs  INTERFERON+RIBAVIRIN Mild diarrhea, irritation or itching 3 No follow-up after 2 months of therapy 1 No follow-up after 3 months of therapy 1 No follow-up after 1 month of therapy 4 Reasons ‘ n’
Comparison of Change in ALT  values  Phlogenzym ®   vs  INTERFERON+RIBAVIRIN Mild diarrhea, irritation or itching 3 No follow-up after 2 months of therapy 1 No follow-up after 3 months of therapy 1 No follow-up after 1 month of therapy 4 Reasons ‘ n’
TOLERANCE JUDGMENT BY PATIENTS IN BOTH GROUPS Phlogenzym ®   vs  INTERFERON+RIBAVIRIN Mild diarrhea, irritation or itching 3 No follow-up after 2 months of therapy 1 No follow-up after 3 months of therapy 1 No follow-up after 1 month of therapy 4 Reasons ‘ n’
Mild diarrhea, irritation or itching 3 No follow-up after 2 months of therapy 1 No follow-up after 3 months of therapy 1 No follow-up after 1 month of therapy 4 Reasons ‘ n’ ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Phlogenzym ® INTERFERON AND RIBAVIRIN  SIDE EFFECTS SUBJECTIVE SYMPTOMS
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Phlogenzym ®   vs  INTERFERON+RIBAVIRIN
Comparison of change in PCR at 9 months Phlogenzym ®   vs  INTERFERON+RIBAVIRIN p-value (two-tailed) .8743 t 0.16 df 50  n 22 30 std. dev. 0.63  0.60  mean 1.27  1.30  Interferon Phlogenzym ®
Changes in PCR with   Phlogenzym ®   Phlogenzym ®   vs  INTERFERON+RIBAVIRIN p-value (two-tailed) .0001 t 4.10 df 58  n 30 30 std. dev. 0.00  0.49  mean 1.00  1.37  PCR at VO PCR_V9
Plogenzym ®   vs  INTERFERON+RIBAVIRIN Changes in PCR with   INTERFERON   p-value (two-tailed) .0006 t 3.74 df 40  n 22 20 std. dev. 0.00  0.50  mean 1.00  1.40  V0 V9
Plogenzym ®   vs  INTERFERON+RIBAVIRIN Changes in ALT with   Phlogenzym ®   p-value (two-tailed) .6375 t 0.47 df 58  n 30 30 std. dev. 64.24  54.74  mean 92.3 43.7 ALT_V0 ALT_V9
COMPARISON WITH INTERFERON+RIBAVIRIN Phlogenzym ®   vs  INTERFERON+RIBAVIRIN     Phlogenzym ®   Interferons  Ribavirin Subjective symptoms    CICs Inflammation Kill the Virus
Phlogenzym ®   vs  INTERFERON+RIBAVIRIN Changes in ALT with INTERFERON   p-value (two-tailed) .0002 t 4.06 df 42  n 22 22 std. dev. 39.49  31.38  mean 83.4 27.6  V0 V9
Comparison of Well Being  Parameters at Visit 9 in both groups Phlogenzym ®   vs  INTERFERON+RIBAVIRIN 0.004 0.12 0.02 0 0.002 0.08 0.23 V6 0.45 0.32 0.34 0.19 0.23 0.03 0.42 V4 6.11 4.25 0.32 5.76 0.16 0.21 0.41 V0 Cumulative Score Weight Loss Fever Jaundice Fatigue Vomiting Anorexia
Cost Comparison of  Phlogenzym ®   & INTERFERON  9- Months Treatment Period COST BENEFIT  OF PLHOGENZYM TREATMENT  OVER  INTERFERON TREATMENT (74%) Phlogenzym ®   vs  INTERFERON+RIBAVIRIN Mild diarrhea, irritation or itching 3 No follow-up after 2 months of therapy 1 No follow-up after 3 months of therapy 1 No follow-up after 1 month of therapy 4 Reasons ‘ n’
CONCLUSION Phlogenzym ®  is as effective as  Interferon +Ribavirin for HCV patients.   End of Treatment Response was 40 %  Phlogenzym ®   vs  INTERFERON+RIBAVIRIN
Phlogenzym ®   vs  INTERFERON+RIBAVIRIN Phlogenzym ®   is very well tolerated & is associated with significant improvement in feeling of well being in majority of patients.
Phlogenzym ®   Managing Hepatitis C  with   Efficacy, Safety & Economy
THANKS

More Related Content

What's hot

Management of hepatitis c pma
Management of hepatitis c pmaManagement of hepatitis c pma
Management of hepatitis c pma
drnkhokhar
 
Advances in Management of Hepatitis C
Advances in Management of Hepatitis CAdvances in Management of Hepatitis C
Advances in Management of Hepatitis C
Arun Vasireddy
 
Incidentally detected hepatitis b what next
Incidentally detected hepatitis b   what nextIncidentally detected hepatitis b   what next
Incidentally detected hepatitis b what next
Sanjeev Kumar
 

What's hot (20)

A Comparison of different treatments for Hepatitis C virus (HCV)
A Comparison of different treatments for Hepatitis C virus (HCV)A Comparison of different treatments for Hepatitis C virus (HCV)
A Comparison of different treatments for Hepatitis C virus (HCV)
 
Management of hepatitis c pma
Management of hepatitis c pmaManagement of hepatitis c pma
Management of hepatitis c pma
 
Hepatitis C : Complete Overview and Recent Updates 2019
Hepatitis C : Complete Overview and Recent Updates 2019Hepatitis C : Complete Overview and Recent Updates 2019
Hepatitis C : Complete Overview and Recent Updates 2019
 
Hepatitis c
Hepatitis cHepatitis c
Hepatitis c
 
Hepatitis C
Hepatitis CHepatitis C
Hepatitis C
 
The HCV Treatment Revolution: A View from the Community Health Center
The HCV Treatment Revolution: A View from the Community Health Center The HCV Treatment Revolution: A View from the Community Health Center
The HCV Treatment Revolution: A View from the Community Health Center
 
Advances in Management of Hepatitis C
Advances in Management of Hepatitis CAdvances in Management of Hepatitis C
Advances in Management of Hepatitis C
 
HBV EASL 2017
HBV EASL 2017HBV EASL 2017
HBV EASL 2017
 
Chronic Hepatitis C WHO Guideline 2016
Chronic Hepatitis C WHO Guideline 2016Chronic Hepatitis C WHO Guideline 2016
Chronic Hepatitis C WHO Guideline 2016
 
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis CBCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
BCC4: Pierre Janin on 4 Newer Agents for Hepatitis C
 
Basics of Hepatitis C
Basics of Hepatitis CBasics of Hepatitis C
Basics of Hepatitis C
 
Case Studies: HBeAg Negative Chronic Hepatitis B
Case Studies: HBeAg Negative Chronic Hepatitis B Case Studies: HBeAg Negative Chronic Hepatitis B
Case Studies: HBeAg Negative Chronic Hepatitis B
 
Hbv reactivation
Hbv reactivationHbv reactivation
Hbv reactivation
 
Chronic hepatitis B
Chronic hepatitis BChronic hepatitis B
Chronic hepatitis B
 
Hcv presentation
Hcv presentationHcv presentation
Hcv presentation
 
Incidentally detected hepatitis b what next
Incidentally detected hepatitis b   what nextIncidentally detected hepatitis b   what next
Incidentally detected hepatitis b what next
 
Hepatitis c
Hepatitis c Hepatitis c
Hepatitis c
 
Spectrum of HCV infection
Spectrum of HCV infectionSpectrum of HCV infection
Spectrum of HCV infection
 
Ppt
PptPpt
Ppt
 
Recent Advances in Mangement of viral hepatitis
Recent Advances in Mangement of viral hepatitis Recent Advances in Mangement of viral hepatitis
Recent Advances in Mangement of viral hepatitis
 

Viewers also liked

Hepatitis C Treatment Questions
Hepatitis C Treatment QuestionsHepatitis C Treatment Questions
Hepatitis C Treatment Questions
Jenny Chan
 
FINAL-CHI-Report-Innovation-in-Hepatitis-C-Treatment-July-2014
FINAL-CHI-Report-Innovation-in-Hepatitis-C-Treatment-July-2014FINAL-CHI-Report-Innovation-in-Hepatitis-C-Treatment-July-2014
FINAL-CHI-Report-Innovation-in-Hepatitis-C-Treatment-July-2014
Will Zasadny
 
Recruit(1)
Recruit(1)Recruit(1)
Recruit(1)
wangjiaz
 
Gleevec group presentation#1
Gleevec group presentation#1Gleevec group presentation#1
Gleevec group presentation#1
erussell10
 
Egfr in colorectal
Egfr in colorectalEgfr in colorectal
Egfr in colorectal
Ahmed Allam
 
Advance Non-Small Cell Lung Cancer final
Advance Non-Small Cell Lung Cancer finalAdvance Non-Small Cell Lung Cancer final
Advance Non-Small Cell Lung Cancer final
Tauhid Bhuiyan
 
IMATINIB RESISTANT CML
IMATINIB RESISTANT CMLIMATINIB RESISTANT CML
IMATINIB RESISTANT CML
spa718
 
FLT3 INHIBITORS
FLT3 INHIBITORSFLT3 INHIBITORS
FLT3 INHIBITORS
spa718
 
Gastrointestinal stromal tumor (GIST) dr ridu kumar sharma
Gastrointestinal stromal tumor (GIST)  dr ridu kumar sharmaGastrointestinal stromal tumor (GIST)  dr ridu kumar sharma
Gastrointestinal stromal tumor (GIST) dr ridu kumar sharma
Ridu Kumar Sharma
 

Viewers also liked (20)

Easl recommendations on the treatment of Hepatitis C
Easl recommendations on the treatment of Hepatitis CEasl recommendations on the treatment of Hepatitis C
Easl recommendations on the treatment of Hepatitis C
 
Hepatitis C and its Treatment
Hepatitis C and its TreatmentHepatitis C and its Treatment
Hepatitis C and its Treatment
 
Hepatitis C Treatment Questions
Hepatitis C Treatment QuestionsHepatitis C Treatment Questions
Hepatitis C Treatment Questions
 
FINAL-CHI-Report-Innovation-in-Hepatitis-C-Treatment-July-2014
FINAL-CHI-Report-Innovation-in-Hepatitis-C-Treatment-July-2014FINAL-CHI-Report-Innovation-in-Hepatitis-C-Treatment-July-2014
FINAL-CHI-Report-Innovation-in-Hepatitis-C-Treatment-July-2014
 
New Treatment for hepatitis C: Impact on morbidity and mortality - Dr Helen H...
New Treatment for hepatitis C: Impact on morbidity and mortality - Dr Helen H...New Treatment for hepatitis C: Impact on morbidity and mortality - Dr Helen H...
New Treatment for hepatitis C: Impact on morbidity and mortality - Dr Helen H...
 
CHRONIC HEPATITIS C TREATMENT EXPANSION
CHRONIC HEPATITIS C TREATMENT EXPANSIONCHRONIC HEPATITIS C TREATMENT EXPANSION
CHRONIC HEPATITIS C TREATMENT EXPANSION
 
Recruit(1)
Recruit(1)Recruit(1)
Recruit(1)
 
Gastro Intestinal Stromal Tumours
Gastro Intestinal Stromal TumoursGastro Intestinal Stromal Tumours
Gastro Intestinal Stromal Tumours
 
Chronic Myloid Leukemia overview (CML)
Chronic Myloid Leukemia overview (CML)Chronic Myloid Leukemia overview (CML)
Chronic Myloid Leukemia overview (CML)
 
Gleevec group presentation#1
Gleevec group presentation#1Gleevec group presentation#1
Gleevec group presentation#1
 
Egfr in colorectal
Egfr in colorectalEgfr in colorectal
Egfr in colorectal
 
Advance Non-Small Cell Lung Cancer final
Advance Non-Small Cell Lung Cancer finalAdvance Non-Small Cell Lung Cancer final
Advance Non-Small Cell Lung Cancer final
 
Hodgkin lymphoma presentation
Hodgkin lymphoma presentation Hodgkin lymphoma presentation
Hodgkin lymphoma presentation
 
IMATINIB RESISTANT CML
IMATINIB RESISTANT CMLIMATINIB RESISTANT CML
IMATINIB RESISTANT CML
 
FLT3 INHIBITORS
FLT3 INHIBITORSFLT3 INHIBITORS
FLT3 INHIBITORS
 
Important sites for pediatrician
Important sites for pediatricianImportant sites for pediatrician
Important sites for pediatrician
 
Gastrointestinal stromal tumor (GIST) dr ridu kumar sharma
Gastrointestinal stromal tumor (GIST)  dr ridu kumar sharmaGastrointestinal stromal tumor (GIST)  dr ridu kumar sharma
Gastrointestinal stromal tumor (GIST) dr ridu kumar sharma
 
CML - DIAGNOSIS,MANAGEMENT AND RECENT ADVANCES
CML - DIAGNOSIS,MANAGEMENT AND RECENT ADVANCESCML - DIAGNOSIS,MANAGEMENT AND RECENT ADVANCES
CML - DIAGNOSIS,MANAGEMENT AND RECENT ADVANCES
 
Gastrointestinal stromal tumours ppt
Gastrointestinal stromal tumours pptGastrointestinal stromal tumours ppt
Gastrointestinal stromal tumours ppt
 
Oral tyrosine kinase inhibitors
Oral tyrosine kinase inhibitorsOral tyrosine kinase inhibitors
Oral tyrosine kinase inhibitors
 

Similar to AN INNOVATIVE APPROACH TOWARDS THE TREATMENT of HEPATITIS C

Management of non responders khi
Management of non responders khiManagement of non responders khi
Management of non responders khi
drnkhokhar
 
Multi drug resistant
Multi drug resistantMulti drug resistant
Multi drug resistant
Hiba Ashibany
 
Acid peptic disease nsaids
Acid peptic disease  nsaidsAcid peptic disease  nsaids
Acid peptic disease nsaids
raj kumar
 
C5 Case Study Session of Three Long-Term Survivors with HIV Disease Jayaweera
C5 Case Study Session of Three Long-Term Survivors with HIV Disease JayaweeraC5 Case Study Session of Three Long-Term Survivors with HIV Disease Jayaweera
C5 Case Study Session of Three Long-Term Survivors with HIV Disease Jayaweera
DSHS
 
C6 HIV 201 Armas
C6 HIV 201 ArmasC6 HIV 201 Armas
C6 HIV 201 Armas
DSHS
 

Similar to AN INNOVATIVE APPROACH TOWARDS THE TREATMENT of HEPATITIS C (20)

Management of non responders khi
Management of non responders khiManagement of non responders khi
Management of non responders khi
 
Nhiễm H.pylori.pdf
Nhiễm H.pylori.pdfNhiễm H.pylori.pdf
Nhiễm H.pylori.pdf
 
Ppt
PptPpt
Ppt
 
TB updates.pptx
TB updates.pptxTB updates.pptx
TB updates.pptx
 
Emesis /CINV
Emesis /CINVEmesis /CINV
Emesis /CINV
 
Corporate presentation-(september-2015-corrected)
Corporate presentation-(september-2015-corrected)Corporate presentation-(september-2015-corrected)
Corporate presentation-(september-2015-corrected)
 
Presentasi farmakogenomik
Presentasi farmakogenomikPresentasi farmakogenomik
Presentasi farmakogenomik
 
Pharmacogenetics and therapeutic drug monitoring practice
Pharmacogenetics and therapeutic drug monitoring practicePharmacogenetics and therapeutic drug monitoring practice
Pharmacogenetics and therapeutic drug monitoring practice
 
Corporate presentation _7_dec_2015
Corporate presentation _7_dec_2015Corporate presentation _7_dec_2015
Corporate presentation _7_dec_2015
 
Multi drug resistant
Multi drug resistantMulti drug resistant
Multi drug resistant
 
Corporate presentation-september-2015-corrected
Corporate presentation-september-2015-correctedCorporate presentation-september-2015-corrected
Corporate presentation-september-2015-corrected
 
Proton Pump Inhibitors
Proton Pump InhibitorsProton Pump Inhibitors
Proton Pump Inhibitors
 
Antiretroviral therapy failure
Antiretroviral therapy failureAntiretroviral therapy failure
Antiretroviral therapy failure
 
Acid peptic disease nsaids
Acid peptic disease  nsaidsAcid peptic disease  nsaids
Acid peptic disease nsaids
 
C5 Case Study Session of Three Long-Term Survivors with HIV Disease Jayaweera
C5 Case Study Session of Three Long-Term Survivors with HIV Disease JayaweeraC5 Case Study Session of Three Long-Term Survivors with HIV Disease Jayaweera
C5 Case Study Session of Three Long-Term Survivors with HIV Disease Jayaweera
 
Biologics in psoriaisis – monitoring guidelines and special scenarios
Biologics in psoriaisis – monitoring guidelines and special scenariosBiologics in psoriaisis – monitoring guidelines and special scenarios
Biologics in psoriaisis – monitoring guidelines and special scenarios
 
C6 HIV 201 Armas
C6 HIV 201 ArmasC6 HIV 201 Armas
C6 HIV 201 Armas
 
Asthma_Medication.pdf
Asthma_Medication.pdfAsthma_Medication.pdf
Asthma_Medication.pdf
 
VONAPRAZAN presentation.pptx
VONAPRAZAN  presentation.pptxVONAPRAZAN  presentation.pptx
VONAPRAZAN presentation.pptx
 
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...
Analyzing ASCO 2016: Developments, takeaways, and implications from the confe...
 

More from icsp

Knowledge and attitude of health care workers regarding blood borne pathogens
Knowledge and attitude of health care workers regarding blood borne pathogensKnowledge and attitude of health care workers regarding blood borne pathogens
Knowledge and attitude of health care workers regarding blood borne pathogens
icsp
 
Hytadid Disease
Hytadid DiseaseHytadid Disease
Hytadid Disease
icsp
 
DENGUE FEVER
DENGUE FEVERDENGUE FEVER
DENGUE FEVER
icsp
 
BLOOD SCREENING :AntiHBc and NAT-Necessity or Luxury
BLOOD SCREENING :AntiHBc and NAT-Necessity or LuxuryBLOOD SCREENING :AntiHBc and NAT-Necessity or Luxury
BLOOD SCREENING :AntiHBc and NAT-Necessity or Luxury
icsp
 
Safe Blood
Safe BloodSafe Blood
Safe Blood
icsp
 
PREVENTION OF MATERNAL AND FETAL INFECTION
PREVENTION OF MATERNAL AND FETAL INFECTIONPREVENTION OF MATERNAL AND FETAL INFECTION
PREVENTION OF MATERNAL AND FETAL INFECTION
icsp
 
ROLE OF INFECTION CONTROL IN DERMATOLOGY
ROLE OF INFECTION CONTROL IN DERMATOLOGYROLE OF INFECTION CONTROL IN DERMATOLOGY
ROLE OF INFECTION CONTROL IN DERMATOLOGY
icsp
 
Precautions to Prevent Transmission of Infectious Agents Among Patients and P...
Precautions to Prevent Transmission of Infectious Agents Among Patients and P...Precautions to Prevent Transmission of Infectious Agents Among Patients and P...
Precautions to Prevent Transmission of Infectious Agents Among Patients and P...
icsp
 

More from icsp (15)

Knowledge and attitude of health care workers regarding blood borne pathogens
Knowledge and attitude of health care workers regarding blood borne pathogensKnowledge and attitude of health care workers regarding blood borne pathogens
Knowledge and attitude of health care workers regarding blood borne pathogens
 
Hytadid Disease
Hytadid DiseaseHytadid Disease
Hytadid Disease
 
DENGUE FEVER
DENGUE FEVERDENGUE FEVER
DENGUE FEVER
 
BLOOD SCREENING :AntiHBc and NAT-Necessity or Luxury
BLOOD SCREENING :AntiHBc and NAT-Necessity or LuxuryBLOOD SCREENING :AntiHBc and NAT-Necessity or Luxury
BLOOD SCREENING :AntiHBc and NAT-Necessity or Luxury
 
Safe Blood
Safe BloodSafe Blood
Safe Blood
 
PREVENTION OF MATERNAL AND FETAL INFECTION
PREVENTION OF MATERNAL AND FETAL INFECTIONPREVENTION OF MATERNAL AND FETAL INFECTION
PREVENTION OF MATERNAL AND FETAL INFECTION
 
ROLE OF INFECTION CONTROL IN DERMATOLOGY
ROLE OF INFECTION CONTROL IN DERMATOLOGYROLE OF INFECTION CONTROL IN DERMATOLOGY
ROLE OF INFECTION CONTROL IN DERMATOLOGY
 
Precautions to Prevent Transmission of Infectious Agents Among Patients and P...
Precautions to Prevent Transmission of Infectious Agents Among Patients and P...Precautions to Prevent Transmission of Infectious Agents Among Patients and P...
Precautions to Prevent Transmission of Infectious Agents Among Patients and P...
 
PREVENTION OF FUNGAL INFECTIONS
PREVENTION OF FUNGAL INFECTIONS PREVENTION OF FUNGAL INFECTIONS
PREVENTION OF FUNGAL INFECTIONS
 
Infection Control in Countries with Limited Resources
Infection Control in Countries with Limited Resources Infection Control in Countries with Limited Resources
Infection Control in Countries with Limited Resources
 
Gloves, Alcohol Hand Rubs, Soap and Water: Which? When? Why?
Gloves, Alcohol Hand Rubs, Soap and Water: Which? When? Why?Gloves, Alcohol Hand Rubs, Soap and Water: Which? When? Why?
Gloves, Alcohol Hand Rubs, Soap and Water: Which? When? Why?
 
HEALTHY DWELLING HEALTHY COMMUNITY
HEALTHY DWELLING HEALTHY COMMUNITY HEALTHY DWELLING HEALTHY COMMUNITY
HEALTHY DWELLING HEALTHY COMMUNITY
 
Infection Control Practices Under the Microscope
Infection Control Practices Under the Microscope  Infection Control Practices Under the Microscope
Infection Control Practices Under the Microscope
 
Global challenges with BBV transmission in health
Global challenges with BBV transmission in health Global challenges with BBV transmission in health
Global challenges with BBV transmission in health
 
Strategies in Waste Management in low income countries
Strategies in Waste Management in low income countries Strategies in Waste Management in low income countries
Strategies in Waste Management in low income countries
 

Recently uploaded

Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
chetankumar9855
 
Russian Call Girls Lucknow Just Call 👉👉7877925207 Top Class Call Girl Service...
Russian Call Girls Lucknow Just Call 👉👉7877925207 Top Class Call Girl Service...Russian Call Girls Lucknow Just Call 👉👉7877925207 Top Class Call Girl Service...
Russian Call Girls Lucknow Just Call 👉👉7877925207 Top Class Call Girl Service...
adilkhan87451
 
Call Girls in Gagan Vihar (delhi) call me [🔝 9953056974 🔝] escort service 24X7
Call Girls in Gagan Vihar (delhi) call me [🔝  9953056974 🔝] escort service 24X7Call Girls in Gagan Vihar (delhi) call me [🔝  9953056974 🔝] escort service 24X7
Call Girls in Gagan Vihar (delhi) call me [🔝 9953056974 🔝] escort service 24X7
9953056974 Low Rate Call Girls In Saket, Delhi NCR
 

Recently uploaded (20)

Most Beautiful Call Girl in Bangalore Contact on Whatsapp
Most Beautiful Call Girl in Bangalore Contact on WhatsappMost Beautiful Call Girl in Bangalore Contact on Whatsapp
Most Beautiful Call Girl in Bangalore Contact on Whatsapp
 
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
Call Girl In Pune 👉 Just CALL ME: 9352988975 💋 Call Out Call Both With High p...
 
Best Rate (Patna ) Call Girls Patna ⟟ 8617370543 ⟟ High Class Call Girl In 5 ...
Best Rate (Patna ) Call Girls Patna ⟟ 8617370543 ⟟ High Class Call Girl In 5 ...Best Rate (Patna ) Call Girls Patna ⟟ 8617370543 ⟟ High Class Call Girl In 5 ...
Best Rate (Patna ) Call Girls Patna ⟟ 8617370543 ⟟ High Class Call Girl In 5 ...
 
Independent Call Girls In Jaipur { 8445551418 } ✔ ANIKA MEHTA ✔ Get High Prof...
Independent Call Girls In Jaipur { 8445551418 } ✔ ANIKA MEHTA ✔ Get High Prof...Independent Call Girls In Jaipur { 8445551418 } ✔ ANIKA MEHTA ✔ Get High Prof...
Independent Call Girls In Jaipur { 8445551418 } ✔ ANIKA MEHTA ✔ Get High Prof...
 
Jogeshwari ! Call Girls Service Mumbai - 450+ Call Girl Cash Payment 90042684...
Jogeshwari ! Call Girls Service Mumbai - 450+ Call Girl Cash Payment 90042684...Jogeshwari ! Call Girls Service Mumbai - 450+ Call Girl Cash Payment 90042684...
Jogeshwari ! Call Girls Service Mumbai - 450+ Call Girl Cash Payment 90042684...
 
Models Call Girls In Hyderabad 9630942363 Hyderabad Call Girl & Hyderabad Esc...
Models Call Girls In Hyderabad 9630942363 Hyderabad Call Girl & Hyderabad Esc...Models Call Girls In Hyderabad 9630942363 Hyderabad Call Girl & Hyderabad Esc...
Models Call Girls In Hyderabad 9630942363 Hyderabad Call Girl & Hyderabad Esc...
 
VIP Hyderabad Call Girls Bahadurpally 7877925207 ₹5000 To 25K With AC Room 💚😋
VIP Hyderabad Call Girls Bahadurpally 7877925207 ₹5000 To 25K With AC Room 💚😋VIP Hyderabad Call Girls Bahadurpally 7877925207 ₹5000 To 25K With AC Room 💚😋
VIP Hyderabad Call Girls Bahadurpally 7877925207 ₹5000 To 25K With AC Room 💚😋
 
Premium Call Girls In Jaipur {8445551418} ❤️VVIP SEEMA Call Girl in Jaipur Ra...
Premium Call Girls In Jaipur {8445551418} ❤️VVIP SEEMA Call Girl in Jaipur Ra...Premium Call Girls In Jaipur {8445551418} ❤️VVIP SEEMA Call Girl in Jaipur Ra...
Premium Call Girls In Jaipur {8445551418} ❤️VVIP SEEMA Call Girl in Jaipur Ra...
 
Call Girls Vasai Virar Just Call 9630942363 Top Class Call Girl Service Avail...
Call Girls Vasai Virar Just Call 9630942363 Top Class Call Girl Service Avail...Call Girls Vasai Virar Just Call 9630942363 Top Class Call Girl Service Avail...
Call Girls Vasai Virar Just Call 9630942363 Top Class Call Girl Service Avail...
 
Premium Bangalore Call Girls Jigani Dail 6378878445 Escort Service For Hot Ma...
Premium Bangalore Call Girls Jigani Dail 6378878445 Escort Service For Hot Ma...Premium Bangalore Call Girls Jigani Dail 6378878445 Escort Service For Hot Ma...
Premium Bangalore Call Girls Jigani Dail 6378878445 Escort Service For Hot Ma...
 
Andheri East ) Call Girls in Mumbai Phone No 9004268417 Elite Escort Service ...
Andheri East ) Call Girls in Mumbai Phone No 9004268417 Elite Escort Service ...Andheri East ) Call Girls in Mumbai Phone No 9004268417 Elite Escort Service ...
Andheri East ) Call Girls in Mumbai Phone No 9004268417 Elite Escort Service ...
 
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 9332606886 𖠋 Will You Mis...
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 9332606886 𖠋 Will You Mis...The Most Attractive Hyderabad Call Girls Kothapet 𖠋 9332606886 𖠋 Will You Mis...
The Most Attractive Hyderabad Call Girls Kothapet 𖠋 9332606886 𖠋 Will You Mis...
 
Russian Call Girls Lucknow Just Call 👉👉7877925207 Top Class Call Girl Service...
Russian Call Girls Lucknow Just Call 👉👉7877925207 Top Class Call Girl Service...Russian Call Girls Lucknow Just Call 👉👉7877925207 Top Class Call Girl Service...
Russian Call Girls Lucknow Just Call 👉👉7877925207 Top Class Call Girl Service...
 
Coimbatore Call Girls in Coimbatore 7427069034 genuine Escort Service Girl 10...
Coimbatore Call Girls in Coimbatore 7427069034 genuine Escort Service Girl 10...Coimbatore Call Girls in Coimbatore 7427069034 genuine Escort Service Girl 10...
Coimbatore Call Girls in Coimbatore 7427069034 genuine Escort Service Girl 10...
 
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
 
Low Rate Call Girls Bangalore {7304373326} ❤️VVIP NISHA Call Girls in Bangalo...
Low Rate Call Girls Bangalore {7304373326} ❤️VVIP NISHA Call Girls in Bangalo...Low Rate Call Girls Bangalore {7304373326} ❤️VVIP NISHA Call Girls in Bangalo...
Low Rate Call Girls Bangalore {7304373326} ❤️VVIP NISHA Call Girls in Bangalo...
 
Trichy Call Girls Book Now 9630942363 Top Class Trichy Escort Service Available
Trichy Call Girls Book Now 9630942363 Top Class Trichy Escort Service AvailableTrichy Call Girls Book Now 9630942363 Top Class Trichy Escort Service Available
Trichy Call Girls Book Now 9630942363 Top Class Trichy Escort Service Available
 
Call Girls Raipur Just Call 9630942363 Top Class Call Girl Service Available
Call Girls Raipur Just Call 9630942363 Top Class Call Girl Service AvailableCall Girls Raipur Just Call 9630942363 Top Class Call Girl Service Available
Call Girls Raipur Just Call 9630942363 Top Class Call Girl Service Available
 
Call Girls in Gagan Vihar (delhi) call me [🔝 9953056974 🔝] escort service 24X7
Call Girls in Gagan Vihar (delhi) call me [🔝  9953056974 🔝] escort service 24X7Call Girls in Gagan Vihar (delhi) call me [🔝  9953056974 🔝] escort service 24X7
Call Girls in Gagan Vihar (delhi) call me [🔝 9953056974 🔝] escort service 24X7
 
Independent Call Girls Service Mohali Sector 116 | 6367187148 | Call Girl Ser...
Independent Call Girls Service Mohali Sector 116 | 6367187148 | Call Girl Ser...Independent Call Girls Service Mohali Sector 116 | 6367187148 | Call Girl Ser...
Independent Call Girls Service Mohali Sector 116 | 6367187148 | Call Girl Ser...
 

AN INNOVATIVE APPROACH TOWARDS THE TREATMENT of HEPATITIS C

  • 1. AN INNOVATIVE APPROACH TOWARDS THE TREATMENT of HEPATITIS C Prof. Dr. Aftab Mohsin Medical Unit III Services Hospital, Lahore.
  • 3. BACKGROUND Hepatitis C related chronic liver disease is common and may result in devastating outcome. The standard treatment World wide is Interferon and Ribavirin combination.
  • 4.
  • 5. HYDROLYTIC ENZYMES + RUTOSID … .a new perspective in the management of Hepatitis C viral infections
  • 6.
  • 7.
  • 8.
  • 9. Phlogenzym ® with INTERFERON+RIBAVIRIN; a comparative study of efficacy and tolerability in patients with HCV infection
  • 10. OBJECTIVE To compare the efficacy & tolerability of Phlogenzym ® vs standard therapy (Interferon & Ribavirin) in patients with HCV infections. Phlogenzym ® vs INTERFERON+RIBAVIRIN
  • 11. STUDY OVERVIEW Idea Conceived In July 2003 Principal Investigator Identified 05-01-04 IRB –Approval 18-05-04 MoH Approval 25-03-05
  • 12. STUDY OVERVIEW Study Began 25-01-05 Patients Screened 12-02-05 First Patient enrolled(V0) 27-03-05 First Patient completed(V6) 28-09-05 Study Presentation on 25-03-06
  • 13.
  • 14.
  • 15.
  • 16. Study Design Phlogenzym ® vs INTERFERON+RIBAVIRIN For 6-months For 9-months Conventional Dosage 2 Tablets,3-times a day ½ hr before meals 30-patients recruited; 22-patients completed 39-patients recruited; 30 -patients completed. Interferon+Ribavirin Phlogenzym ®
  • 17.
  • 18.
  • 19. Genotype Distribution in recruited patients Phlogenzym ® vs INTERFERON+RIBAVIRIN 1 0 1  2 2 3 17 25 3  6 4 Interferon Arm (Reference Drug) 6 6 Phlogenzym Arm (Test Drug) Untypable 3  Description
  • 20. Phlogenzym ® vs INTERFERON+RIBAVIRIN Genotype Distribution in recruited patients
  • 21. Previous Medical History in Recruited Patients Phlogenzym ® vs INTERFERON+RIBAVIRIN 30 0 Interferon Arm (Reference Drug) 32 7 Phlogenzym Arm (Test Drug) Naive Non Responders to Interferon Description
  • 22. Previous Medical History in Recruited Patients Phlogenzym ® vs INTERFERON+RIBAVIRIN
  • 23. COMPLIANCE STATUS Phlogenzym ® vs INTERFERON+RIBAVIRIN 8 22 Interferon Arm (Reference Drug) 9 30 Phlogenzym Arm (Test Drug) Dropped Out Trial Completed Description
  • 24. DETAILS OF INTERFERON ARM DROP OUT PATIENTS Phlogenzym ® vs INTERFERON+RIBAVIRIN Withdraw due to decrease TLC after 1 month of therapy 1 High grade fever after 1 month of therapy 1 Epistaxis after 1 month of therapy 1 H. Zoster after 4 months of therapy 1 Changed Physician after 1 month of therapy 4 REASONS ‘ n’
  • 25. DETAILS OF Phlogenzym ® ARM DROP OUT PATIENTS Phlogenzym ® vs INTERFERON+RIBAVIRIN Mild diarrhea, irritation or itching 3 No follow-up after 2 months of therapy 1 No follow-up after 3 months of therapy 1 No follow-up after 1 month of therapy 4 Reasons ‘ n’
  • 26. GENDER DISTRIBUTION IN PATIENTS WHO COMPLETED THERAPY Phlogenzym ® vs INTERFERON+RIBAVIRIN Mild diarrhea, irritation or itching 3 No follow-up after 2 months of therapy 1 No follow-up after 3 months of therapy 1 No follow-up after 1 month of therapy 4 Reasons ‘ n’ 14 8 Interferon Arm (Reference Drug) 13 17 Phlogenzym ® Arm (Test Drug) Female Male Description
  • 27. Phlogenzym ® vs INTERFERON+RIBAVIRIN GENOTYPE DISTRIBUTION IN PATIENTS WHO COMPLETED THERAPY Mild diarrhea, irritation or itching 3 No follow-up after 2 months of therapy 1 No follow-up after 3 months of therapy 1 No follow-up after 1 month of therapy 4 Reasons ‘ n’ 2 2 3 12 20 3  5 3 Interferon Arm (Reference Drug) 4 4 Phlogenzym ® Arm (Test Drug) Untypable 3  Description
  • 28. Phlogenzym ® vs INTERFERON+RIBAVIRIN GENOTYPE DISTRIBUTION IN PATIENTS WHO COMPLETED THERAPY Mild diarrhea, irritation or itching 3 No follow-up after 2 months of therapy 1 No follow-up after 3 months of therapy 1 No follow-up after 1 month of therapy 4 Reasons ‘ n’
  • 29. PREVIOUS MEDICAL HISTORY IN PATIENTS WHO COMPLETED THERAPY Phlogenzym ® vs INTERFERON+RIBAVIRIN Mild diarrhea, irritation or itching 3 No follow-up after 2 months of therapy 1 No follow-up after 3 months of therapy 1 No follow-up after 1 month of therapy 4 Reasons ‘ n’ 22 0 Interferon Arm (Reference Drug) 26 4 Phlogenzym ® Arm (Test Drug) Naive Non Responders to Interferon Description
  • 30. Phlogenzym ® vs INTERFERON+RIBAVIRIN PREVIOUS MEDICAL HISTORY IN PATIENTS WHO COMPLETED THERAPY Mild diarrhea, irritation or itching 3 No follow-up after 2 months of therapy 1 No follow-up after 3 months of therapy 1 No follow-up after 1 month of therapy 4 Reasons ‘ n’
  • 31.
  • 32. PCR –VE PATIENTS DISTRIBUTION Phlogenzym ® vs INTERFERON+RIBAVIRIN Mild diarrhea, irritation or itching 3 No follow-up after 2 months of therapy 1 No follow-up after 3 months of therapy 1 No follow-up after 1 month of therapy 4 Reasons ‘ n’
  • 33.
  • 34. Comparison of Change in ALT values Phlogenzym ® vs INTERFERON+RIBAVIRIN Mild diarrhea, irritation or itching 3 No follow-up after 2 months of therapy 1 No follow-up after 3 months of therapy 1 No follow-up after 1 month of therapy 4 Reasons ‘ n’
  • 35. TOLERANCE JUDGMENT BY PATIENTS IN BOTH GROUPS Phlogenzym ® vs INTERFERON+RIBAVIRIN Mild diarrhea, irritation or itching 3 No follow-up after 2 months of therapy 1 No follow-up after 3 months of therapy 1 No follow-up after 1 month of therapy 4 Reasons ‘ n’
  • 36.
  • 37.
  • 38. Comparison of change in PCR at 9 months Phlogenzym ® vs INTERFERON+RIBAVIRIN p-value (two-tailed) .8743 t 0.16 df 50 n 22 30 std. dev. 0.63 0.60 mean 1.27 1.30 Interferon Phlogenzym ®
  • 39. Changes in PCR with Phlogenzym ® Phlogenzym ® vs INTERFERON+RIBAVIRIN p-value (two-tailed) .0001 t 4.10 df 58 n 30 30 std. dev. 0.00 0.49 mean 1.00 1.37 PCR at VO PCR_V9
  • 40. Plogenzym ® vs INTERFERON+RIBAVIRIN Changes in PCR with INTERFERON p-value (two-tailed) .0006 t 3.74 df 40 n 22 20 std. dev. 0.00 0.50 mean 1.00 1.40 V0 V9
  • 41. Plogenzym ® vs INTERFERON+RIBAVIRIN Changes in ALT with Phlogenzym ® p-value (two-tailed) .6375 t 0.47 df 58 n 30 30 std. dev. 64.24 54.74 mean 92.3 43.7 ALT_V0 ALT_V9
  • 42. COMPARISON WITH INTERFERON+RIBAVIRIN Phlogenzym ® vs INTERFERON+RIBAVIRIN     Phlogenzym ®   Interferons  Ribavirin Subjective symptoms  CICs Inflammation Kill the Virus
  • 43. Phlogenzym ® vs INTERFERON+RIBAVIRIN Changes in ALT with INTERFERON p-value (two-tailed) .0002 t 4.06 df 42 n 22 22 std. dev. 39.49 31.38 mean 83.4 27.6 V0 V9
  • 44. Comparison of Well Being Parameters at Visit 9 in both groups Phlogenzym ® vs INTERFERON+RIBAVIRIN 0.004 0.12 0.02 0 0.002 0.08 0.23 V6 0.45 0.32 0.34 0.19 0.23 0.03 0.42 V4 6.11 4.25 0.32 5.76 0.16 0.21 0.41 V0 Cumulative Score Weight Loss Fever Jaundice Fatigue Vomiting Anorexia
  • 45. Cost Comparison of Phlogenzym ® & INTERFERON 9- Months Treatment Period COST BENEFIT OF PLHOGENZYM TREATMENT OVER INTERFERON TREATMENT (74%) Phlogenzym ® vs INTERFERON+RIBAVIRIN Mild diarrhea, irritation or itching 3 No follow-up after 2 months of therapy 1 No follow-up after 3 months of therapy 1 No follow-up after 1 month of therapy 4 Reasons ‘ n’
  • 46. CONCLUSION Phlogenzym ® is as effective as Interferon +Ribavirin for HCV patients. End of Treatment Response was 40 % Phlogenzym ® vs INTERFERON+RIBAVIRIN
  • 47. Phlogenzym ® vs INTERFERON+RIBAVIRIN Phlogenzym ® is very well tolerated & is associated with significant improvement in feeling of well being in majority of patients.
  • 48. Phlogenzym ® Managing Hepatitis C with Efficacy, Safety & Economy